Drugs / Naltrexone/bupropion extended-release
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03799198 | Jan 2019 → May 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Naltrexone/bupropion extended-release | “Naltrexone/bupropion extended-release (Contrave® pills, p.o.)” NCT03799198 ↗ |
| Known as | Contrave | “Naltrexone/bupropion extended-release (Contrave® pills, p.o.)” NCT03799198 ↗ |